Published in PLoS One on August 10, 2012
Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging. PLoS One (2013) 1.08
The protective effects of beta-casomorphin-7 against glucose -induced renal oxidative stress in vivo and vitro. PLoS One (2013) 0.86
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther (2014) 0.83
Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction. Antioxid Redox Signal (2013) 0.81
Cyclic nucleotide signalling in kidney fibrosis. Int J Mol Sci (2015) 0.80
Vasodilator responses to acetylcholine are not mediated by the activation of soluble guanylate cyclase or TRPV4 channels in the rat. Am J Physiol Heart Circ Physiol (2014) 0.80
Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS One (2013) 0.78
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther (2017) 0.75
Stimulators of soluble guanylyl cyclase: future clinical indications. Ochsner J (2013) 0.75
Global and societal implications of the diabetes epidemic. Nature (2001) 25.18
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Structural-functional relationships in diabetic nephropathy. J Clin Invest (1984) 4.78
A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis (2005) 4.17
Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation (2005) 4.08
Mouse models of diabetic nephropathy. J Am Soc Nephrol (2009) 3.74
Proteinuria and the risk of developing end-stage renal disease. Kidney Int (2003) 3.73
T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation (1999) 3.41
The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil (2010) 3.20
Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol (2007) 3.08
Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest (1986) 2.96
NO-independent regulatory site on soluble guanylate cyclase. Nature (2001) 2.67
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab (2008) 2.34
Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol (2007) 1.95
Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun (1998) 1.86
Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol (2006) 1.82
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens (2005) 1.73
Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest (1997) 1.73
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int (2002) 1.68
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J (2008) 1.58
Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care (2007) 1.50
Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension (2006) 1.50
The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens (2002) 1.42
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens (2005) 1.40
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem (2009) 1.36
Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol (1999) 1.24
Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int (2000) 1.21
Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol (2002) 1.20
New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord (2008) 1.20
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens (2010) 1.15
Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant (2000) 1.12
Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. J Diabetes Complications (2008) 1.08
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One (2011) 1.04
eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am J Pathol (2009) 1.01
The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Ren Fail (2001) 1.01
Endothelial dysfunction is correlated with microalbuminuria in children with short-duration type 1 diabetes. Diabetes Care (2005) 1.00
Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy. Nat Rev Nephrol (2011) 0.99
Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am J Physiol Renal Physiol (2005) 0.98
A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol (2000) 0.97
Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol (2010) 0.95
Early detection of endothelial injury and dysfunction in conjunction with correction of hemodynamic maladjustment can effectively restore renal function in type 2 diabetic nephropathy. Clin Hemorheol Microcirc (2006) 0.95
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care (2007) 0.93
Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res (2009) 0.90
Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol (2006) 0.89
ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats. J Hypertens (2000) 0.88
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int (2005) 0.88
NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney Int (2003) 0.85
Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press Res (2007) 0.83
Increased expression of tumor necrosis factor-alpha in diabetic macrovasculopathy. Cardiovasc Pathol (2000) 0.83
Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis. Kidney Int (2004) 0.81
Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol (2004) 0.81
Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol (1996) 0.80
Comorbidities in UK patients at the start of renal replacement therapy (chapter 6). Nephrol Dial Transplant (2007) 0.77
Role of endocytosis in cellular uptake of sex steroids. Cell (2005) 3.49
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med (2010) 2.12
New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. Nat Genet (2012) 1.90
A systematic approach to managing pregnant dialysis patients--the importance of an intensified haemodiafiltration protocol. Nephrol Dial Transplant (2005) 1.87
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension (2007) 1.84
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens (2005) 1.73
Low birth weight, a risk factor for cardiovascular diseases in later life, is already associated with elevated fetal glycosylated hemoglobin at birth. Circulation (2006) 1.61
Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem (2003) 1.61
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation (2006) 1.55
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation. Hypertension (2009) 1.54
Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens (2004) 1.51
Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension (2006) 1.50
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med (2014) 1.48
Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension (2011) 1.46
NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol (2009) 1.45
No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. Nephrol Dial Transplant (2004) 1.43
Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. Circ Heart Fail (2009) 1.43
New evidence for the fetal insulin hypothesis: fetal angiotensinogen M235T polymorphism is associated with birth weight and elevated fetal total glycated hemoglobin at birth. J Hypertens (2010) 1.41
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem (2009) 1.36
Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem (2010) 1.34
Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res (2009) 1.29
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol (2005) 1.21
Concentrations of carotenoids, retinol and alpha-tocopherol in plasma and follicular fluid of women undergoing IVF. Hum Reprod (2003) 1.19
The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl (2013) 1.18
Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol (2011) 1.17
Evidence that kidney function but not type 2 diabetes determines retinol-binding protein 4 serum levels. Diabetes (2008) 1.16
Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab (2012) 1.15
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens (2010) 1.15
Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research. Kidney Blood Press Res (2012) 1.12
Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. Eur J Pharmacol (2005) 1.11
Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension (2004) 1.08
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol (2007) 1.07
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One (2011) 1.07
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J (2013) 1.06
Nucleotidyl cyclase activity of soluble guanylyl cyclase α1β1. Biochemistry (2011) 1.05
Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung (2008) 1.05
Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J (2002) 1.05
DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res (2012) 1.05
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am J Physiol Heart Circ Physiol (2011) 1.04
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One (2011) 1.04
BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur Heart J (2009) 1.04
Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo. Mol Pharmacol (2007) 1.04
Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci (2004) 1.03
Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. Atherosclerosis (2010) 1.00
Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Lett (2006) 1.00
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One (2012) 1.00
Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J Hypertens (2014) 0.99
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol (2003) 0.99
Pregnancy on intensified hemodialysis: fetal surveillance and perinatal outcome. Fetal Diagn Ther (2007) 0.99
Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol (2004) 0.98
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc (2013) 0.98
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol (2014) 0.98
Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation (2002) 0.97
Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J (2010) 0.97
Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs (2011) 0.96
Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg (2010) 0.96
The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol (2012) 0.96
Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med (2007) 0.96
Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2011) 0.95
Prematurity is related to high placental cortisol in preeclampsia. Pediatr Res (2009) 0.95
Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol (2012) 0.95
NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol (2006) 0.95
ETB receptor deficiency causes salt-sensitive hypertension. J Mol Med (Berl) (2002) 0.95
A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today (2011) 0.94
Isoforms of retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver. Lipids Health Dis (2008) 0.94
Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer (2005) 0.94
Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol (2010) 0.94
Renal elimination of troponin T and troponin I. Clin Chem (2003) 0.94
Retinol-binding protein 4 and its membrane receptor STRA6 control adipogenesis by regulating cellular retinoid homeostasis and retinoic acid receptor α activity. Mol Cell Biol (2013) 0.92
Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics (2004) 0.91
Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. Proc Natl Acad Sci U S A (2012) 0.90
Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure. J Am Soc Nephrol (2006) 0.90
Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res (2009) 0.90
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation (2003) 0.89